HRP20221454T1 - Piridinamin-piridonski i pirimidinamin-piridonski spojevi - Google Patents

Piridinamin-piridonski i pirimidinamin-piridonski spojevi Download PDF

Info

Publication number
HRP20221454T1
HRP20221454T1 HRP20221454TT HRP20221454T HRP20221454T1 HR P20221454 T1 HRP20221454 T1 HR P20221454T1 HR P20221454T T HRP20221454T T HR P20221454TT HR P20221454 T HRP20221454 T HR P20221454T HR P20221454 T1 HRP20221454 T1 HR P20221454T1
Authority
HR
Croatia
Prior art keywords
pyridyl
pyridin
trifluoromethyl
alkyl
phenyl
Prior art date
Application number
HRP20221454TT
Other languages
English (en)
Inventor
Johan LINDSTRÖM
Rickard Forsblom
Tobias Ginman
Fredrik Rahm
Jenny Viklund
Original Assignee
Sprint Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sprint Bioscience Ab filed Critical Sprint Bioscience Ab
Publication of HRP20221454T1 publication Critical patent/HRP20221454T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (15)

1. Spoj formule (I) [image] pri čemu R1 je fenil ili monociklični 5-6 člani heteroaril, svaki po izboru supstituiran sa jednim ili više supstituenata odabranih od halogena, C1-C6alkila, C3-C4cikloalkila, C1-C6alkoksi, C1-C6haloalkila, C1-C6haloalkoksi, amino, N-C1-C3alkilamino i N,N-diC1-C3alkilamino; R2 je odabran od vodika, C1-C3haloalkila i C1-C3alkila; R3 je odabran od A, fenila i monocikličnog heteroarila, pri čemu je navedeni fenil i navedeni heteroaril svaki po izboru supstituiran sa jednim ili više R4, R5, R6 i R7; R4, R5, R6 i R7 su nezavisno odabrani od halogena, C1-C6alkila, C3-C4cikloalkila, C1-C6alkoksi, C1-C6haloalkila, C1-C6haloalkoksi, azetidina, amino, N-C1-C3alkilamino, N,N-diC1-C3alkilamino, NHSO2R8, SO2R9 i hidroksi; R8 je C1-C3haloalkil ili C1-C3alkil; R9 je odabran od R10, C1-C6alkila, amino, N-C1-C3alkilamino, N,N-diC1-C3alkilamino i C1-C3alkoksiC1-C3alkila, pri čemu je navedeni C1-C6alkil i C1-C3alkoksiC1-C3alkil svaki po izboru supstituiran sa jednim R10 i/ili jednim ili više halogena; R10 je odabran od fenila, benzila, monocikličnog heteroarila, C3-C6cikloalkila, heterociklila, od kojih je svaki po izboru supstituiran sa jednim ili više R11; R11 je odabran od halogena, C1-C3haloalkila, C3-C4cikloalkila, C1-C3alkila, amino, N-C1-C3alkilamino, N,N-diC1-C3alkilamino i C1-C3alkoksiC1-C3alkila; A je [image] R12 je odabran od vodika, halogena, COR13, C1-C6alkila, C3-C6cikloalkila, C1-C3alkoksiC1-C3alkila, C1-C6alkoksi, C1-C3cijanoalkila, i C1-C3haloalkila; R13 je odabran od C1-C3alkoksi, N-C1-C3alkilamino, N,N-diC1-C3alkilamino, 1-pirolidinila, 1-piperidinila i 1-azetidinila; Y je odabran od CH2, S, SO, SO2, NR14, NCOR9, NCOOR15, NSO2R9, NCOCH2R9, O, ili veze; R14 je odabran od H, C1-C3haloalkila, C1-C3alkoksiC1-C3alkila, C1-C3alkila, i C3-C6cikloalkila; R15 je odabran od R10, C1-C6alkila i C1-C3alkoksiC1-C3alkila, i pri čemu je navedeni C1-C6alkil i C1-C3alkoksiC1-C3alkil svaki po izboru supstituiran sa jednim R10 i/ili jednim ili više halogena; i Z je CH ili N; ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema patentnom zahtjevu 1, pri čemu R2 je vodik; ili njegova farmaceutski prihvatljiva sol.
3. Spoj prema patentnom zahtjevu 1 ili 2, pri čemu R1 je fenil ili monociklični 5-6 člani heteroaril, svaki po izboru supstituiran sa jednim ili više supstituenata odabranih od C1-C6alkila, C3-C4cikloalkila, i halogena; ili njegova farmaceutski prihvatljiva sol.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu R1 je odabran od fenila, pirimidinila, oksazolila, imidazolila, pirazolila i tiazolila, svaki po izboru supstituiran sa jednim ili više supstituenata odabranih od halogena, C1-C6alkila, C3-C4cikloalkila, i C1-C6haloalkila; ili njegova farmaceutski prihvatljiva sol.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu R3 je odabran od A, fenila, piridila, tienila, furila, pirimidinila i pirazolila, svaki po izboru i nezavisno supstituiran sa jednim ili više R4 ili R5; ili njegova farmaceutski prihvatljiva sol.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu R3 je odabran od fenila, piridila, morfolinila, piperidila, pirolidinila, tienila, i piperazinila, svaki po izboru supstituiran sa jednim ili više supstituenata odabranih od halogena, C1-C6alkila, C1-C6haloalkila i C3-C4cikloalkila; ili njegova farmaceutski prihvatljiva sol.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu R1 je fenil ili monociklični 5-6 člani heteroaril svaki po izboru supstituiran sa jednim ili više supstituenata odabranih od halogena, C1-C6alkila, C1-C6haloalkila, i C3-C4cikloalkila; R2 je vodik; i R3 je fenil ili monociklični 5-6 člani heteroaril svaki po izboru supstituiran sa jednim ili više supstituenata odabranih od halogena, C1-C6alkila, C1-C6haloalkila i C3-C4cikloalkila; ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu R1 je odabran od fenila, pirimidinila, oksazolila, imidazolila, ili tiazolila, svaki po izboru supstituiran sa jednim ili više supstituenata odabranih od halogena, C1-C6alkila, C1-C6haloalkila, i C3-C4cikloalkila; R2 je vodik; R3 je odabran od fenila, piridila, pirazolila, pirolidinila, i tienila, svaki po izboru supstituiran sa jednim ili više supstituenata odabranih od halogena, C1-C6alkila, C1-C6haloalkila, C3-C4cikloalkila; ili A; Y je CH2, O, NSO2-C1-C6alkil ili NSO2-benzil, pri čemu je navedeni benzil po izboru supstituiran sa jednim ili više halogena; i R12 je C1-C6alkil ili C1-C6haloalkil; ili njegova farmaceutski prihvatljiva sol.
9. Spoj prema patentnom zahtjevu 1, pri čemu R1 je fenil, 2-metilpirimidin-4-il, oksazol-2-il, 2-metiltiazol-4-il, 2-metilpirazol-3-il, i 1-metilimidazol-4-il; R2 je vodik; R3 je odabran od 2-klorofenila, 3-piridila, 4-piridila, 1-morfolinila, 2-(trifluorometil)-1-piperidila, 3-(trifluorometil)morfolin-4-ila, 4-[(4-fluorofenil)metilsulfonil]-2-(trifluorometil)piperazin-1-ila, 4-etilsulfonil-2-(trifluorometil)piperazin-1-ila; 2-(trifluorometil)fenila, 4-metil-piridin-3-ila, 2-(trifluorometil)-piridin-3-ila i 1-etil-3-(trifluorometil)pirazol-4-ila; i Z je CH ili N; ili njegova farmaceutski prihvatljiva sol.
10. Spoj prema patentnom zahtjevu 1, pri čemu je spoj odabran od 4-(2-anilinopirimidin-4-il)-6-(2-klorofenil)-1H-piridin-2-ona; 4-(2-Anilinopirimidin-4-il)-6-(3-piridil)-1H-piridin-2-ona; 4-(2-Anilinopirimidin-4-il)-6-(4-piridil)-1H-piridin-2-ona 4-(2-anilinopirimidin-4-il)-6-morfolino-1H-piridin-2-ona; 4-[2-[(2-Metilpirimidin-4-il)amino]-4-piridil]-6-[2-(trifluorometil)-1-piperidil]-1H-piridin-2-ona; 4-(2-Anilinopirimidin-4-il)-6-[2-(trifluorometil)-1-piperidil]-1H-piridin-2-ona; 4-[2-[(2-Metilpirimidin-4-il)amino]-4-piridil]-6-[3-(trifluorometil)morfolin-4-il]-1H-piridin-2-ona; 4-(2-Anilinopirimidin-4-il)-6-[3-(trifluorometil)morfolin-4-il]-1H-piridin-2-ona; 6-[4-[(4-Fluorofenil)metilsulfonil]-2-(trifluorometil)piperazin-1-il]-4-[2-[(2-metilpirimidin-4-il)amino]-4-piridil]-1H-piridin-2-ona; 6-[4-Etilsulfonil-2-(trifluorometil)piperazin-1-il]-4-[2-[(2-metilpirimidin-4-il)amino]-4-piridil]-1H-piridin-2-ona; 4-[2-(Oksazol-2-ilamino)-4-piridil]-6-[3-(trifluorometil)morfolin-4-il]-1H-piridin-2-ona; 4-[2-[(2-Metiltiazol-4-il)amino]-4-piridil]-6-[3-(trifluorometil)morfolin-4-il]-1H-piridin-2-ona; 4-[2-[(2-metilpirimidin-4-il)amino]-4-piridil]-6-[2-(trifluorometil)-fenil]-1H-piridin-2-ona; 4-[2-[(2-Metilpirazol-3-il)amino]-4-piridil]-6-[2-(trifluorometil)fenil]-1H-piridin-2-ona; 4-[2-[(2-Metiltiazol-4-il)amino]-4-piridil]-6-[2-(trifluorometil)fenil]-1H-piridin-2-ona; 6-(4-metil-3-piridil)-4-[2-[(2-metilpirimidin-4-il)amino]-4-piridil]-1H-piridin-2-ona; 4-[2-[(2-metilpirimidin-4-il)amino]-4-piridil]-6-[2-(trifluorometil)-3-piridil]-1H-piridin-2-ona; 6-[1-etil-3-(trifluorometil)pirazol-4-il]-4-[2-[(2-metilpirimidin-4-il)amino]-4-piridil]-1H-piridin-2-ona; 4-[2-[(1-Metilimidazol-4-il)amino]-4-piridil]-6-[2-(trifluorometil)fenil]-1H-piridin-2-ona; i 6-(2-klorofenil)-4-[2-[(2-metilpirimidin-4-il)amino]-4-piridil]-1H-piridin-2-ona, ili njegove farmaceutski prihvatljive soli.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, za primjenu u liječenju ili profilaksi bolesti.
12. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, za primjenu u liječenju raka.
13. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, za primjenu u liječenju dijabetesa tipa II.
14. Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, i farmaceutski prihvatljiv razblaživač, nosač i/ili ekscipijens.
15. Farmaceutska kompozicija, koja sadrži terapijski efikasnu količinu spoja prema patentnom zahtjevu 1, ili njegove farmaceutski prihvatljive soli, i drugi agens protiv raka odabran od alkilirajućih agenasa, antimetabolita, derivata kamptotecina protiv raka, agenasa protiv raka biljnog porijekla, antibiotika, enzima, koordinacijskih kompleksa platine, inhibitora tirozin kinaze, hormona, antagonista hormona, monoklonskih antitijela, interferona, i modifikatora biološkog odgovora.
HRP20221454TT 2017-08-23 2018-08-23 Piridinamin-piridonski i pirimidinamin-piridonski spojevi HRP20221454T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17187560 2017-08-23
EP18759610.1A EP3672948B1 (en) 2017-08-23 2018-08-23 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
PCT/EP2018/072790 WO2019038389A1 (en) 2017-08-23 2018-08-23 PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS

Publications (1)

Publication Number Publication Date
HRP20221454T1 true HRP20221454T1 (hr) 2023-01-20

Family

ID=59686885

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20221454TT HRP20221454T1 (hr) 2017-08-23 2018-08-23 Piridinamin-piridonski i pirimidinamin-piridonski spojevi

Country Status (20)

Country Link
US (2) US11208423B2 (hr)
EP (2) EP3672948B1 (hr)
JP (2) JP7201260B2 (hr)
KR (1) KR20200044024A (hr)
CN (3) CN111094271B (hr)
AU (2) AU2018320418B2 (hr)
CA (1) CA3073129A1 (hr)
DK (1) DK3672948T3 (hr)
ES (1) ES2929424T3 (hr)
FI (1) FI3672948T3 (hr)
HR (1) HRP20221454T1 (hr)
HU (1) HUE060805T2 (hr)
IL (3) IL292488B2 (hr)
LT (1) LT3672948T (hr)
PL (1) PL3672948T3 (hr)
PT (1) PT3672948T (hr)
RS (1) RS63795B1 (hr)
SI (1) SI3672948T1 (hr)
TW (2) TW202325302A (hr)
WO (1) WO2019038389A1 (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3672948T (lt) * 2017-08-23 2022-12-27 Sprint Bioscience Ab Piridinamino-piridono ir pirimidinamino-piridono junginiai
RU2020124116A (ru) 2017-12-22 2022-01-25 Хиберселл, Инк. Производные арил-бипиридинамина в качестве ингибиторов фосфатидилинозитолфосфаткиназы
US20220184077A1 (en) * 2020-11-25 2022-06-16 Deciphera Pharmaceuticals, Llc Anti-viral activity of vps34 inhibitors
AU2022326573A1 (en) * 2021-08-13 2024-02-15 Deciphera Pharmaceuticals, Llc Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer
WO2023205465A1 (en) * 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234628B2 (en) * 2002-05-21 2007-08-23 Amgen Inc. Substituted heterocyclic compounds and methods of use
CN103270026A (zh) * 2010-12-21 2013-08-28 诺瓦提斯公司 作为vps34抑制剂的联-杂芳基化合物
SI2655375T1 (sl) 2010-12-23 2015-03-31 Sanofi Derivati pirimidinona, njihova priprava in njihova farmacevtska uporaba
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
EP3094326A4 (en) 2014-01-14 2017-07-26 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN105916503B (zh) 2014-01-14 2020-04-14 米伦纽姆医药公司 杂芳基化合物和其用途
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
CN108884067B (zh) 2016-02-19 2021-01-08 思普瑞特生物科学公司 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物
LT3416945T (lt) * 2016-02-19 2020-11-25 Sprint Bioscience Ab 6-aril-4-(morfolin-4-il)-1h-piridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui
LT3672948T (lt) * 2017-08-23 2022-12-27 Sprint Bioscience Ab Piridinamino-piridono ir pirimidinamino-piridono junginiai

Also Published As

Publication number Publication date
CN116041321A (zh) 2023-05-02
CN116041320A (zh) 2023-05-02
WO2019038389A1 (en) 2019-02-28
IL292488B2 (en) 2023-09-01
CN111094271A (zh) 2020-05-01
CA3073129A1 (en) 2019-02-28
PT3672948T (pt) 2022-11-07
EP3672948B1 (en) 2022-10-05
TWI785102B (zh) 2022-12-01
HUE060805T2 (hu) 2023-04-28
TW201912638A (zh) 2019-04-01
CN111094271B (zh) 2023-02-28
US11208423B2 (en) 2021-12-28
TW202325302A (zh) 2023-07-01
EP3672948A1 (en) 2020-07-01
US11780858B2 (en) 2023-10-10
IL292488A (en) 2022-06-01
EP4169581A1 (en) 2023-04-26
AU2023204378A1 (en) 2023-08-03
JP2023021316A (ja) 2023-02-10
DK3672948T3 (da) 2022-12-05
US20200361963A1 (en) 2020-11-19
ES2929424T3 (es) 2022-11-29
IL272808A (en) 2020-04-30
JP7201260B2 (ja) 2023-01-10
LT3672948T (lt) 2022-12-27
US20220177495A1 (en) 2022-06-09
IL272808B (en) 2022-06-01
JP2020531488A (ja) 2020-11-05
IL292488B1 (en) 2023-05-01
KR20200044024A (ko) 2020-04-28
FI3672948T3 (fi) 2023-01-13
SI3672948T1 (sl) 2023-01-31
AU2018320418A1 (en) 2020-04-09
RU2020110505A3 (hr) 2022-02-24
RU2020110505A (ru) 2021-09-23
PL3672948T3 (pl) 2022-12-05
AU2018320418B2 (en) 2023-04-06
IL302293A (en) 2023-06-01
RS63795B1 (sr) 2022-12-30

Similar Documents

Publication Publication Date Title
HRP20221454T1 (hr) Piridinamin-piridonski i pirimidinamin-piridonski spojevi
HRP20210094T1 (hr) POSTUPAK PRIPRAVE DERIVATIVA OKSAZOLO[4,5-b]PIRIDINA I TIAZOLO[4,5-b]PIRIDINA KAO INHIBITORA IRAK4 NAMIJENJENIH LIJEČENJU RAKA
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
RU2413726C2 (ru) Замещенные биарильные аналоги пиперазинилпиридина, их применение в терапии, фармацевтическая композиция, фармацевтический препарат, способы уменьшения проводимости кальция и ингибирования связывания капсаициновых рецепторов
HRP20201337T1 (hr) Inhibitori lizin-specifične demetilaze-1
HRP20141190T1 (hr) Disupstituirani derivati piridina kao antikancerogena sredstva
RU2013124101A (ru) Гетероциклические амины и их применения
RU2010125220A (ru) Ненуклеозидные ингибиторы обратной транскриптазы
JP2012525395A5 (hr)
HRP20230657T1 (hr) Spojevi i pripravci za liječenje hematoloških poremećaja
RU2015100942A (ru) Производное пиперидинилпиразолпиридина
HRP20140265T1 (hr) Derivat aminopirazina i odgovarajuä†i lijek
JP2013544256A5 (hr)
HRP20201400T1 (hr) Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa
JP2006500348A5 (hr)
JP2006509715A5 (hr)
JP2020531488A5 (hr)
JP2010513444A5 (hr)
JP2019505595A5 (hr)
SI3083586T1 (en) The new carboxamides, the process of their manufacture, the pharmaceutical preparations they contain and their use for the manufacture of medicinal products
JP2011520908A5 (hr)
JP2017505794A5 (hr)
RU2014110172A (ru) Гетероциклическое производное и фармацевтическое средство
HRP20220414T1 (hr) Inhibitori lizin specifične demetilaze-1
RU2011114487A (ru) Гетероциклические соединения как ингибиторы протеинкиназы